The synthetic biology firm had total revenues of $19.3 million and withdrew its financial guidance for fiscal year 2020 citing uncertainty caused by COVID-19.
The company holds and licenses a variety of IP related to high-throughput genotyping, sample pooling, and methods involved in oligonucleotide ligation-based assays.
Some of the market's most influential voices, including Kári Stefánsson and Linda Avey, believe that consumer genomics is not on the way out but rather experiencing a period of transition.
Assemblies of two basmati rice genomes enabled researchers to trace the origins of the rice variety and could help pinpoint desired rice genes for breeding.
The deal follows a number of recent acquisitions in the animal genomics space for Neogen including Canadian animal genomics firm Delta Genomics Centre.
The firm said it plans to sign between five and 10 additional biopharma collaborations in fiscal year 2020, some with milestone and royalty payment structures.
